Personalized Drug Discovery: HCA Approach Optimized for Rare Diseases at Tel Aviv University

Title:Personalized Drug Discovery: HCA Approach Optimized for Rare Diseases at Tel Aviv University

Volume: 17 Issue: 3

Author(s): Leonardo J. Solmesky and Miguel Weil

Affiliation:

Keywords: Drug repurposing, high content screening, nanomaterials characterization, personalized drug discovery, personalized medicine, rare diseases.

Abstract: The Cell screening facility for personalized medicine (CSFPM) at Tel Aviv University in Israel is devoted to screening small molecules libraries for finding new drugs for rare diseases using human cell based models. The main strategy of the facility is based on smartly reducing the size of the compounds collection in similarity clusters and at the same time keeping high diversity of pharmacophores. This strategy allows parallel screening of several patient derived - cells in a personalized screening approach. The tested compounds are repositioned drugs derived from collections of phase III and FDA approved small molecules. In addition, the facility carries screenings using other chemical libraries and toxicological characterizations of nanomaterials.

Cite this article as:

Solmesky J. Leonardo and Weil Miguel, Personalized Drug Discovery: HCA Approach Optimized for Rare Diseases at Tel Aviv University, Combinatorial Chemistry & High Throughput Screening 2014; 17 (3) . https://dx.doi.org/10.2174/1386207317666140109123249